Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11:35am EDT
Price Change (% chg)

€0.10 (+1.15%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ABLX.BR


Ablynx NV is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a class of therapeutic proteins based on single-domain antibody fragments, for a range of human diseases, including inflammation, haematology, oncology and pulmonary disease. The Company has approximately 25 programs in the pipeline... (more)


Beta: 1.43
Market Cap (Mil.): €470.27
Shares Outstanding (Mil.): 53.99
Dividend: --
Yield (%): --


  ABLX.BR Industry Sector
P/E (TTM): -- 102.18 35.85
EPS (TTM): -0.41 -- --
ROI: -49.31 -0.10 18.25
ROE: -49.99 -0.88 19.12
Search Stocks

BRIEF-Ablynx raises 41.7 mln euros through private placement

Announces that it has raised 41,720,822 through a private placement of new shares via an accelerated

30 Jun 2014

BRIEF-Ablynx's anti-vWF nanobody, caplacizumab, achieves clinical proof-of-concept in phase II titan study

* Ablynx's anti-vwf nanobody, caplacizumab, achieves clinical proof-of-concept in phase ii titan study

17 Jun 2014

Belgium's Ablynx increases cash position after Merck payment

BRUSSELS, May 14 - Belgian biotech group Ablynx said its cash reserves increased in the first quarter after an upfront payment from Merck & Co as part of a research deal for immune oncology.

14 May 2014

BRIEF-Ablynx posts Q1 net loss 2.8 mln euros

* Anticipated that top-line phase II data from Titan study with Caplacizumab will be reported in June 2014

14 May 2014

BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie

* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie

23 Apr 2014

BRIEF-Ablynx reports 34 pct jump in FY revenue

BRUSSELS, Feb 27 - Ablynx NV : * Says FY revenue growth of 34 pct to 35.9 million euros * Says net loss for the period reduced by 32 pct to 19.5 million euros (2012: 28.5 million euros) * Says fourfold increase in cash-income from collaborations to 157.6 million euros (2012: 36.5 million euros)

27 Feb 2014

Belgium's Ablynx expects higher cash burn in 2014

BRUSSELS, Feb 27 - Belgian biopharmaceutical company Ablynx reported a 34 percent rise in revenue in 2013 and ended the year with a large cash pile, although cautioned that it would burn through more of it this year than last.

27 Feb 2014

Ablynx agrees Merck cancer deal worth up to 1.7 billion euros

BRUSSELS - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.

03 Feb 2014

Ablynx signs Merck deal worth up to 1.7 bln euros

BRUSSELS, Feb 3 - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.29 billion) to develop potential new treatments for cancer.

03 Feb 2014

BRIEF-Ablynx, Merck sign cancer immunotherapy collaboration, licensing agreement

BRUSSELS, Feb 3 - Ablynx NV : * Announces worldwide cancer immunotherapy discovery collaboration and licensing agreement with Merck * Collaboration, licensing agreement is focused on the discovery and development of several predefined nanobody candidates * Co will receive an upfront payment of 20 mln euros; up to 10.7 mln euros in research funding during the initial three year * Is eligible to receive development, regulatory and commercial milestone payments on achieved sales thre

03 Feb 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks